Tango Therapeutics, Inc. (TNGX) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$24.16

From 52W high−29.54%

Volume2.46M

Market cap$3.91B

P/E (TTM)—

P/S (TTM)72.6x

Div yield—

Key dataNov 4, 2026

Open

$24.16

From 52W high

−29.54%

Volume

2.46M

Market cap

$3.91B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−24.0x

P/E (TTM)

—

RSI (14)

48.6

MomentumView details →

1D Return

+0.04%

YTD Return

+160.16%

SummaryUpdated Jun 1, 2026

Tango Therapeutics, Inc. (NASDAQ:TNGX) is a biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company went public in September 2020 through a special purpose acquisition company (SPAC) merger. Tango focuses on discovering and developing targeted cancer therapies using a precision medicine approach called synthetic lethality, where drugs are designed to selectively kill cancer cells with specific genetic vulnerabilities while sparing healthy cells.

Ask drillr about Tango Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−24.0x

EV/Sales

54.4x

P/S (TTM)

72.6x

P/B (TTM)

3.8x

ProfitabilityView details →

Gross Margin

98.25%

Net Margin

−229.92%

EBITDA Margin

−226.46%

ROE (TTM)

−12.08%

ROA (TTM)

−11.52%

Asset Turnover

0.07x

GrowthView details →

Revenue YoY

+121.47%

EPS YoY

+35.61%

FCF YoY

+3.28%

Revenue CAGR 3Y

+35.89%

EPS CAGR 3Y

+26.89%

EBITDA YoY

+18.74%

MomentumView details →

1D Return

+0.04%

YTD Return

+160.16%

1Y Return

+206.93%

RSI (14)

48.6

vs 50D SMA

−1.92%

vs 200D SMA

+2.52%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

50.82x

Quick Ratio

50.82x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.37

EPS Surprise

−16.64%

Beats (12Q)

3/12

Next Q EPS Est

−$0.38

Avg Surprise (4Q)

298.05%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

53.81M

Net Income (TTM)

−123.72M

Op. CF (TTM)

−143.90M

Latest newsMore news →

Tango Therapeutics, Inc. and Erasca, Inc. announced that their Phase 1/2 study of vopimetostat combined with ERAS-0015 is open for enrollment in patients with specified MTAP-deleted cancers.10h ago

Tango Therapeutics, Inc. shares fell 16.4%.9d ago

Similar companies

丰倍生物603334.SH Iovance Biotherapeutics, Inc.IOVA Relay Therapeutics, Inc.RLAY 南模生物688265.SH 科兴制药688136.SH Catalyst Pharmaceuticals, Inc.CPRX Find similar companies →

Latest newsMore news →

Tango Therapeutics, Inc. and Erasca, Inc. announced that their Phase 1/2 study of vopimetostat combined with ERAS-0015 is open for enrollment in patients with specified MTAP-deleted cancers.10h ago Tango Therapeutics, Inc. shares fell 16.4%.9d ago Tango Therapeutics, Inc. shared Phase 1/2 trial data for investigational vopimetostat in advanced pancreatic and lung cancers.12d ago